BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, Wong BC, Dent J, Wu PC. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology. 1997;25:241-244. [PMID: 8985298 DOI: 10.1002/hep.510250144] [Cited by in Crossref: 164] [Cited by in F6Publishing: 157] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Delaney WE 4th, Miller TG, Isom HC. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chemother 1999;43:2017-26. [PMID: 10428929 DOI: 10.1128/AAC.43.8.2017] [Cited by in Crossref: 52] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
2 Fan ST, Cheung ST, Lo CM. Indications for liver transplantation in patients with chronic hepatitis B and C virus infection and hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15 Suppl:E181-6. [PMID: 10921405 DOI: 10.1046/j.1440-1746.2000.02119.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
3 Lau GK, Kwong Lee C, Liang R. Hepatitis B virus infection and bone marrow transplantation. Critical Reviews in Oncology/Hematology 1999;31:71-6. [DOI: 10.1016/s1040-8428(98)00042-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wong DK, Yuen MF, Tse E, Yuan H, Sum SS, Hui CK, Lai CL. Detection of intrahepatic hepatitis B virus DNA and correlation with hepatic necroinflammation and fibrosis. J Clin Microbiol 2004;42:3920-4. [PMID: 15364969 DOI: 10.1128/JCM.42.9.3920-3924.2004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
5 Pai SB, Bozdayi AM, Pai RB, Beker T, Sarioglu M, Turkyilmaz AR, Grier J, Yurdaydin C, Schinazi RF. Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy. Antimicrob Agents Chemother 2005;49:2618-24. [PMID: 15980328 DOI: 10.1128/AAC.49.7.2618-2624.2005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Dusheiko G. Lamivudine Therapy for Hepatitis B Infection. Scandinavian Journal of Gastroenterology 2009;34:76-81. [DOI: 10.1080/003655299750025589] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
7 Pichoud C, Seignères B, Wang Z, Trépo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology. 1999;29:230-237. [PMID: 9862871 DOI: 10.1002/hep.510290119] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 3.6] [Reference Citation Analysis]
8 Chang UI, Lee YC, Wie SH, Jang JW, Bae SH, Choi JY, Yang JM, Yoon SK, Sun HS. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy. J Med Virol 2007;79:902-10. [PMID: 17516533 DOI: 10.1002/jmv.20819] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
9 Gish RG, Locarnini S. Genotyping and genomic sequencing in clinical practice. Clin Liver Dis 2007;11:761-95, viii. [PMID: 17981228 DOI: 10.1016/j.cld.2007.08.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
10 Walters KA, Tipples GA, Allen MI, Condreay LD, Addison WR, Tyrrell L. Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening. Antimicrob Agents Chemother 2003;47:1936-42. [PMID: 12760870 DOI: 10.1128/AAC.47.6.1936-1942.2003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Wakil SM, Kazim SN, Khan LA, Raisuddin S, Parvez MK, Guptan RC, Thakur V, Hasnain SE, Sarin SK. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus. J Med Virol. 2002;68:311-318. [PMID: 12226816 DOI: 10.1002/jmv.10205] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
12 Soemohardjo S. New options in the treatment of chronic hepatitis. Adv Exp Med Biol. 2003;531:191-198. [PMID: 12916791 DOI: 10.1007/978-1-4615-0059-9_15] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
13 Brown TJ, Vander Straten M, Tyring SK. ANTIVIRAL AGENTS. Dermatologic Clinics 2001;19:23-34. [DOI: 10.1016/s0733-8635(05)70227-8] [Cited by in Crossref: 16] [Article Influence: 0.8] [Reference Citation Analysis]
14 Akuta N, Kumada H. Influence of hepatitis B virus genotypes on the response to antiviral therapies. J Antimicrob Chemother. 2005;55:139-142. [PMID: 15618285 DOI: 10.1093/jac/dkh533] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
15 Tassopoulos NC. Chronic hepatitis B: interferon - monotherapy or combination with nucleoside analogues? Liver 1998;18:71-2. [DOI: 10.1111/j.1600-0676.1998.tb00131.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
16 Fontaine H, Thiers V, Chrétien Y, Zylberberg H, Poupon RE, Bréchot C, Legendre C, Kreis H, Pol S. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation. 2000;69:2090-2094. [PMID: 10852602 DOI: 10.1097/00007890-200005270-00020] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 3.0] [Reference Citation Analysis]
17 Ze E, Baek EK, Lee JJ, Chung HW, Ahn DG, Cho HJ, Kwon JC, Kim HJ, Lee H. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. Clin Mol Hepatol 2014;20:267-73. [PMID: 25320730 DOI: 10.3350/cmh.2014.20.3.267] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
18 Peng J, Zhao Y, Mai J, Pang WK, Wei X, Zhang P, Xu Y. Inhibition of hepatitis B virus replication by various RNAi constructs and their pharmacodynamic properties. J Gen Virol. 2005;86:3227-3234. [PMID: 16298967 DOI: 10.1099/vir.0.81171-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
19 Kajino K, Kamiya N, Yuasa S, Takahara T, Sakurai J, Yamamura K, Hino O. Evaluation of Anti-Hepatitis B Virus (HBV) Drugs Using the HBV Transgenic Mouse: Application of the Semiquantitative Polymerase Chain Reaction (PCR) for Serum HBV DNA to Monitor the Drug Efficacy. Biochemical and Biophysical Research Communications 1997;241:43-8. [DOI: 10.1006/bbrc.1997.7766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
20 Lu HY, Zhuang LW, Yu YY, Si CW, Li J, Zhang JJ, Zeng Z, Chen XY, Han ZH, Chen Y. Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol 2008; 14(8): 1268-1273 [PMID: 18300356 DOI: 10.3748/wjg.14.1268] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
21 Brook MG. European guideline for the management of hepatitis B and C virus infections. Int J STD AIDS 2001;12:48-57. [DOI: 10.1258/0956462011923930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
22 Abdelhamed AM, Kelley CM, Miller TG, Furman PA, Isom HC. Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment. J Virol. 2002;76:8148-8160. [PMID: 12134020 DOI: 10.1128/jvi.76.16.8148-8160.2002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
23 Colacino JM, Staschke KA. The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Prog Drug Res 1998;50:259-322. [PMID: 9670781 DOI: 10.1007/978-3-0348-8833-2_6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 1.6] [Reference Citation Analysis]
24 Xiong X, Yang H, Westland CE, Zou R, Gibbs CS. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology. 2000;31:219-224. [PMID: 10613749 DOI: 10.1002/hep.510310132] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 2.5] [Reference Citation Analysis]
25 Chin R, Locarnini S. Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol. 2003;13:255-272. [PMID: 12820187 DOI: 10.1002/rmv.393] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 1.4] [Reference Citation Analysis]
26 Wu KL, Zhang X, Zhang J, Yang Y, Mu YX, Liu M, Lu L, Li Y, Zhu Y, Wu J. Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatment. Virus Res. 2005;112:100-107. [PMID: 16022904 DOI: 10.1016/j.virusres.2005.04.001] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 2.2] [Reference Citation Analysis]
27 Soon DK, Lowe SL, Teng CH, Yeo KP, McGill J, Wise SD. Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection. J Hepatol 2004;41:852-8. [PMID: 15519660 DOI: 10.1016/j.jhep.2004.07.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
28 Poortahmasebi V, Malekzadeh R, Montazeri G, Fakhari E, Norouzi M, Khamseh A, Mahmoodi Karkhaneh M, Tavakoli A, Jazayeri SM. Lamivudine Resistance and Precore Variants in Iranian Patients With Chronic Hepatitis B: Correlation With Virological and Clinical Features. Jundishapur J Microbiol 2015;8:e20262. [PMID: 26487918 DOI: 10.5812/jjm.20262] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Wu F, Wu MJ, Zhuge XL, Zhu SM, Zhu B. Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment. Hepatobiliary Pancreat Dis Int 2012;11:172-6. [PMID: 22484586 DOI: 10.1016/s1499-3872(12)60144-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
30 Chen CH, Lee CM, Lu SN, Wang JH, Tung HD, Hung CH, Chen WJ, Changchien CS. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol. 2004;41:454-461. [PMID: 15336449 DOI: 10.1016/j.jhep.2004.04.032] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
31 Wang JP, Bai XF, Zhang SQ, Li JG, Zhang Y, Zhang Y, Xue KC, Gu Y, Wang PZ, Luo KX. Anti-HBV effect of targeted lamivudy palmitate solid lipid nano-particles. Shijie Huaren Xiaohua Zazhi 2003; 11(2): 191-194 [DOI: 10.11569/wcjd.v11.i2.191] [Reference Citation Analysis]
32 Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut. 2002;51:597-599. [PMID: 12235087 DOI: 10.1136/gut.51.4.597] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 3.5] [Reference Citation Analysis]
33 Umeoka F, Iwasaki Y, Matsumura M, Takaki A, Kobashi H, Tatsukawa M, Shiraha H, Fujioka S, Sakaguchi K, Shiratori Y. Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients. J Gastroenterol 2006;41:693-701. [PMID: 16933008 DOI: 10.1007/s00535-006-1834-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
34 Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology. 1998;27:1711-1716. [PMID: 9620347 DOI: 10.1002/hep.510270634] [Cited by in Crossref: 289] [Cited by in F6Publishing: 273] [Article Influence: 12.0] [Reference Citation Analysis]
35 Buti M, Cotrina M, Jardi R, de Castro EC, Rodriguez-Frias F, Sánchez-Avila F, Esteban R, Guardia J. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat. 2001;8:270-275. [PMID: 11454178 DOI: 10.1046/j.1365-2893.2001.00296.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 1.6] [Reference Citation Analysis]
36 Craxì A, Antonucci G, Cammà C. Treatment options in HBV. Journal of Hepatology 2006;44:S77-83. [DOI: 10.1016/j.jhep.2005.11.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
37 Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology. 1999;29:939-945. [PMID: 10051501 DOI: 10.1002/hep.510290340] [Cited by in Crossref: 123] [Cited by in F6Publishing: 112] [Article Influence: 5.3] [Reference Citation Analysis]
38 Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, Buchan S, Boxall L, O'Donnell K, Shaw J, Hübscher S, Elias E. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000;46:107-13. [PMID: 10601065 DOI: 10.1136/gut.46.1.107] [Cited by in Crossref: 112] [Cited by in F6Publishing: 103] [Article Influence: 5.1] [Reference Citation Analysis]
39 Loo WT, Cheung MN, Chow LW. Fructus schisandrae (Wuweizi)-containing compound inhibits secretion of HBsAg and HBeAg in hepatocellular carcinoma cell line. Biomedicine & Pharmacotherapy 2007;61:606-10. [DOI: 10.1016/j.biopha.2007.08.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
40 Zhu W, Xie K, Xu Y, Wang L, Chen K, Zhang L, Fang J. CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse. Virus Res 2016;217:125-32. [PMID: 27049051 DOI: 10.1016/j.virusres.2016.04.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
41 Amini-Bavil-Olyaee S, Hosseini SY, Sabahi F, Alavian SM. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine. Int J Infect Dis. 2008;12:83-87. [PMID: 17698384 DOI: 10.1016/j.ijid.2007.05.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
42 Gilson RJC, Chopra KB, Newell AM, Murray-lyon IM, Nelson MR, Rice SJ, Tedder RS, Toole J, Jaffe HS, Weller IVD. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. Journal of Viral Hepatitis 1999;6:387-95. [DOI: 10.1046/j.1365-2893.1999.00182.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 73] [Article Influence: 3.7] [Reference Citation Analysis]
43 Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41-66. [PMID: 9989342 DOI: 10.2165/00003088-199936010-00004] [Cited by in Crossref: 170] [Cited by in F6Publishing: 167] [Article Influence: 7.4] [Reference Citation Analysis]
44 Lewandowska D, Durlik M, Kukuła K, Cieciura T, Ciecierski R, Walewska-zielecka B, Szmidt J, Rowiński W, Lao M. Treatment of chronic hepatitis B with lamivudine in renal allograft recipients. Transplantation Proceedings 2000;32:1369-70. [DOI: 10.1016/s0041-1345(00)01260-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
45 Dong C, Qu L, Wang H, Wei L, Dong Y, Xiong S. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res. 2015;118:110-117. [PMID: 25843425 DOI: 10.1016/j.antiviral.2015.03.015] [Cited by in Crossref: 141] [Cited by in F6Publishing: 131] [Article Influence: 20.1] [Reference Citation Analysis]
46 Maclachlan D, Battegay M, Jacob AL, Tyndall A. Successful treatment of hepatitis B-associated polyarteritis nodosa with a combination of lamivudine and conventional immunosuppressive therapy: a case report. Rheumatology 2000;39:106-8. [DOI: 10.1093/rheumatology/39.1.106] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
47 Poordad F, Gish R. Evolving therapies for the treatment of viral hepatitis. Emerging Drugs 2005;4:15-34. [DOI: 10.1517/14728214.4.1.15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Galan MV, Boyce D, Gordon SC. Current pharmacotherapy for hepatitis B infection. Expert Opin Pharmacother. 2001;2:1289-1298. [PMID: 11584997 DOI: 10.1517/14656566.2.8.1289] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
49 Yamamoto M, Hayashi N, Takehara T, Ueda K, Mita E, Tatsumi T, Sasaki Y, Kasahara A, Hori M. Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells. Hepatology. 1999;30:300-307. [PMID: 10385671 DOI: 10.1002/hep.510300105] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
50 Santantonio T, Mazzola M, Pastore G. Lamivudine is safe and effective in fulminant hepatitis B. J Hepatol. 1999;30:551. [PMID: 10190743 DOI: 10.1016/s0168-8278(99)80119-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
51 Strasser SI, Mcdonald GB. Hepatitis Viruses and Hematopoietic Cell Transplantation: A Guide to Patient and Donor Management. Blood 1999;93:1127-36. [DOI: 10.1182/blood.v93.4.1127] [Cited by in Crossref: 93] [Article Influence: 4.0] [Reference Citation Analysis]
52 Yeo W, Steinberg JL, Tam JS, Chan PK, Leung NW, Lam KC, Mok TS, Johnson PJ. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol. 1999;59:263-269. [PMID: 10502254 DOI: 10.1002/(SICI)1096-9071(199911)59:3%3C263::AID-JMV1%3E3.0.CO;2-X] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 de Vrueh RL, Rump ET, van De Bilt E, van Veghel R, Balzarini J, Biessen EA, van Berkel TJ, Bijsterbosch MK. Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B. Antimicrob Agents Chemother 2000;44:477-83. [PMID: 10681306 DOI: 10.1128/AAC.44.3.477-483.2000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
54 Young JD, Cheeseman CI, Mackey JR, Cass CE, Baldwin SA. Chapter 9 Molecular mechanisms of nucleoside and nucleoside drug transport. Gastrointestinal transport molecular physiology. Elsevier; 2000. pp. 329-78. [DOI: 10.1016/s1063-5823(00)50011-8] [Cited by in Crossref: 14] [Article Influence: 0.6] [Reference Citation Analysis]
55 Sablon E, Shapiro F, Zoulim F. Early detection of hepatitis B drug resistance: implications for patient management. Expert Rev Mol Diagn 2003;3:535-47. [PMID: 14510175 DOI: 10.1586/14737159.3.5.535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
56 Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10-24. [PMID: 10862190 DOI: 10.1097/00000658-200007000-00003] [Cited by in Crossref: 551] [Cited by in F6Publishing: 544] [Article Influence: 25.0] [Reference Citation Analysis]
57 Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology. 2000;32:1163-1169. [PMID: 11050070 DOI: 10.1053/jhep.2000.19618] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 1.9] [Reference Citation Analysis]
58 Mahabadi M, Alavian SM, Norouzi M, Keyvani H, Mahmoudi M, Jazayeri SM. Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B. Electron Physician 2016;8:2466-74. [PMID: 27504160 DOI: 10.19082/2466] [Reference Citation Analysis]
59 Previsani N, Lavanchy D, J. Zuckerman A. Hepatitis B. Viral Hepatitis: Molecular Biology, Diagnosis, Epidemiology and Control. Elsevier; 2003. pp. 31-97. [DOI: 10.1016/s0168-7069(03)10002-x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
60 Gish RG. Current treatment and future directions in the management of chronic hepatitis B viral infection. Clin Liver Dis. 2005;9:541-565, v. [PMID: 16207563 DOI: 10.1016/j.cld.2005.08.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
61 Scotto G, Fazio V, Campanozzi F, D'adduzio A. Efficacy of treatment with lamivudine in patients with chronic active E-minus variant hepatitis B virus infection: A nonrandomized, open-label study. Current Therapeutic Research 2000;61:321-30. [DOI: 10.1016/s0011-393x(00)80001-6] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
62 Lee SK, Park YH, Lee WY, Kim SJ, Choi SH, Joh JW, Lee JH, Koh KC, Kim YI, Lee BB. Orthotopic liver transplantation in HBs-antigen positive patients: short-term results. Transplant Proc 1998;30:3314-5. [PMID: 9838465 DOI: 10.1016/s0041-1345(98)01044-6] [Reference Citation Analysis]
63 Shen Y, Jia Y, Zhou J, Ji J, Xun P. Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs. Clin Drug Investig 2019;39:835-46. [PMID: 31228017 DOI: 10.1007/s40261-019-00802-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Tomasiewicz K, Modrzewska R, Krawczuk G, Lyczak A. Lamivudine therapy for chronic hepatitis B virus infection and pregnancy: a case report. Int J Infect Dis. 2001;5:115-116. [PMID: 11468109 DOI: 10.1016/S1201-9712(01)90038-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
65 Li XM, Yang YB, Hou HY, Shi ZJ, Shen HM, Teng BQ, Li AM, Shi MF, Zou L. Interruption of HBV intrauterine transmission: A clinical study. World J Gastroenterol 2003; 9(7): 1501-1503 [PMID: 12854150 DOI: 10.3748/wjg.v9.i7.1501] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 83] [Article Influence: 4.5] [Reference Citation Analysis]
66 Barcena Marugan R, Cid Gomez L, Lopez Serrano P. Use of adefovir in the treatment of the chronic hepatitis B virus infection with resistance to lamivudine. Transplant Proc. 2003;35:1841-1843. [PMID: 12962817 DOI: 10.1016/s0041-1345(03)00686-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
67 Fan ST. Liver transplantation in Asia: Problems and practice. J Gastroenterol Hepatol 1998;13:S308-10. [PMID: 28976673 DOI: 10.1111/j.1440-1746.1998.tb01899.x] [Reference Citation Analysis]
68 Liu KZ, Hou W, Zumbika E, Ni Q. Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy. J Zhejiang Univ Sci B. 2005;6:1182-1187. [PMID: 16358376 DOI: 10.1631/jzus.2005.B1182] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
69 Brown TJ, Mccrary M, Tyring SK. Antiviral agents: Nonantiviral drugs. Journal of the American Academy of Dermatology 2002;47:581-99. [DOI: 10.1067/mjd.2002.121033] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
70 Franceschini R, Cataldi A, Tenconi GL, Icardi G, Bruzzone BM. Reactivation of Hepatitis B Virus Infection During Cytotoxic Chemotherapy. American Journal of Gastroenterology 2001;96:606-7. [DOI: 10.1111/j.1572-0241.2001.03573.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
71 Liu X, Schinazi RF. Hepatitis B virus resistance to lamivudine and its clinical implications. Antivir Chem Chemother. 2002;13:143-155. [PMID: 12448687 DOI: 10.1177/095632020201300301] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
72 Jin Oon C, Ning Chen W, Lim N, Koh S, Keow Lim G, Lin Leong A, San Tan G. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the ‘a’ epitope of the surface antigen are sensitive to ganciclovir. Antiviral Research 1999;41:113-8. [DOI: 10.1016/s0166-3542(99)00007-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
73 Ma L, Alla NR, Li X, Mynbaev OA, Shi Z. Mother-to-child transmission of HBV: review of current clinical management and prevention strategies: Mother-to-child transmission of HBV. Rev Med Virol 2014;24:396-406. [DOI: 10.1002/rmv.1801] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
74 Tomita T, Yokosuka O, Tagawa M, Saisho H, Tamura S, Fukuda I, Omata M. Decrease of wild-type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Pekin ducks infected with the viruses. J Hepatol. 2000;32:850-858. [PMID: 10845674 DOI: 10.1016/s0168-8278(00)80256-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
75 Chen CH, Lee CM, Tung WC, Wang JH, Hung CH, Hu TH, Wang JC, Lu SN, Changchien CS. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. J Hepatol 2010;52:478-85. [PMID: 20185198 DOI: 10.1016/j.jhep.2010.01.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
76 Farrell G. Hepatitis B e antigen seroconversion: Effects of lamivudine alone or in combination with interferon alpha. J Med Virol 2000;61:374-9. [DOI: 10.1002/1096-9071(200007)61:3<374::aid-jmv16>3.0.co;2-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
77 Petit M, Guillou DB, Roche B, Dussaix E, Duclos-vallée J, Féray C, Samuel D. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen: HBV DNA and preS1 in Transplant Recipients on 3TC. J Med Virol 2001;65:493-504. [DOI: 10.1002/jmv.2063] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
78 Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G, Gardner SD, Brown N. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. 2003;9:49-56. [PMID: 12514773 DOI: 10.1053/jlts.2003.50005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
79 Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002;36:186-194. [PMID: 12085364 DOI: 10.1053/jhep.2002.34294] [Cited by in Crossref: 217] [Cited by in F6Publishing: 196] [Article Influence: 10.9] [Reference Citation Analysis]
80 Lee WC, Wu MJ, Cheng CH, Chen CH, Shu KH, Lian JD. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001;38:1074-81. [PMID: 11684562 DOI: 10.1053/ajkd.2001.28607] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 2.2] [Reference Citation Analysis]
81 Yang H, Westland CE, Delaney WE 4th, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology. 2002;36:464-473. [PMID: 12143057 DOI: 10.1053/jhep.2002.34740] [Cited by in Crossref: 133] [Cited by in F6Publishing: 111] [Article Influence: 6.7] [Reference Citation Analysis]
82 Broderick A, Jonas MM. Management of hepatitis B in children. Clin Liver Dis 2004;8:387-401. [PMID: 15481346 DOI: 10.1016/j.cld.2004.02.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
83 Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol. 2004;74:361-366. [PMID: 15332287 DOI: 10.1002/jmv.20185] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
84 Bedre RH, Raj U, Misra SP, Varadwaj PK. Antiviral therapy with nucleotide/nucleoside analogues in chronic hepatitis B: A meta-analysis of prospective randomized trials. Indian J Gastroenterol 2016;35:75-82. [PMID: 27083430 DOI: 10.1007/s12664-016-0632-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Ke CZ, Chen Y, Gong ZJ, Meng ZJ, Liu L, Ren ZJ, Zhou ZH. Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment. World J Gastroenterol 2006; 12(25): 4061-4063 [PMID: 16810760 DOI: 10.3748/wjg.v12.i25.4061] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
86 Petrelli E, Balducci M, Pieretti C, Rocchi MB, Clementi M, Manzin A. Lamivudine treatment failure in preventing fatal outcome of de novo severe acute hepatitis B in patients with haematological diseases. Journal of Hepatology 2001;35:823-6. [DOI: 10.1016/s0168-8278(01)00220-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
87 Cheng TL, Chang WW, Su IJ, Lai MD, Huang W, Lei HY, Chang WT. Therapeutic inhibition of hepatitis B virus surface antigen expression by RNA interference. Biochem Biophys Res Commun. 2005;336:820-830. [PMID: 16153600 DOI: 10.1016/j.bbrc.2005.08.173] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
88 Delaney W, Bartholomeusz A, Locarnini SA. Evolving therapies for the treatment of chronic hepatitis B virus infection. Expert Opin Investig Drugs. 2002;11:169-187. [PMID: 11829711 DOI: 10.1517/13543784.11.2.169] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
89 Ishikawa T, Ichida T, Yamagiwa S, Sugahara S, Uehara K, Okoshi S, Asakura H. High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol. 2001;16:1274-1281. [PMID: 11903747 DOI: 10.1046/j.1440-1746.2001.02616.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.6] [Reference Citation Analysis]
90 Kessler HH, Stelzl E, Marth E, Stauber RE. Detection of Mutations in the Hepatitis B Virus Polymerase Gene. Clinical Chemistry 2003;49:989-92. [DOI: 10.1373/49.6.989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
91 Stornaiuolo G, Stanzione M, Brancaccio G, Cuomo G, Precone V, Di Biase S, Felaco FM, Piccinino F, Gaeta GB. Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B. World J Gastroenterol 2007; 13(42): 5642-5647 [PMID: 17948940 DOI: 10.3748/wjg.v13.i42.5642] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
92 Zhou XM, Lin JS, Shi Y, Tian DA, Huang HJ, Zhou HJ, Jin YX. Establishment of a screening system for selection of siRNA target sites directed against hepatitis B virus surface gene. Acta Biochim Biophys Sin (Shanghai) 2005;37:310-6. [PMID: 15880259 DOI: 10.1111/j.1745-7270.2005.00049.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
93 Chen T, He XX, Peng SH, Lin JS, Chang Y, Liu LF. In vitro effects of a novel nucleoside analog beta-LPA against hepatitis B virus. Shijie Huaren Xiaohua Zazhi 2008; 16(10): 1110-1113 [DOI: 10.11569/wcjd.v16.i10.1110] [Reference Citation Analysis]
94 Hantz O, Borel C, Trabaud C, Zoulim F, Dessolin J, Camplo M, Vlieghe P, Bouygues M, Trepo C, Kraus JL. Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles. Antimicrob Agents Chemother 1997;41:2579-81. [PMID: 9371374 DOI: 10.1128/AAC.41.11.2579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
95 Chan TM, Wu PC, Li FK, Lai CL, Cheng IK, Lai KN. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology. 1998;115:177-181. [PMID: 9649474 DOI: 10.1016/s0016-5085(98)70380-4] [Cited by in Crossref: 68] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
96 Buti M, Jardi R, Cotrina M, Rodriguez-Frias F, Esteban R, Guardia J. Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. J Hepatol. 1998;28:510-513. [PMID: 9551691 DOI: 10.1016/s0168-8278(98)80327-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
97 Regev A, Schiff ER. Viral hepatitis A, B, and C. Clin Liver Dis 2000;4:47-71, vi. [PMID: 11232191 DOI: 10.1016/s1089-3261(05)70096-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl. 2000;6:434-439. [PMID: 10915164 DOI: 10.1053/jlts.2000.6446] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 4.3] [Reference Citation Analysis]
99 Hunt CM, Brown NA, Rubin M. Lamivudine therapy of chronic hepatitis B. Adv Exp Med Biol 1999;458:11-21. [PMID: 10549375 DOI: 10.1007/978-1-4615-4743-3_2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
100 Yalcin K, Danis R, Degertekin H, Alp MN, Tekes S, Budak T. The Lack of Effect of Therapeutic Vaccination With a Pre-S2/S HBV Vaccine in the Immune Tolerant Phase of Chronic HBV Infection: . Journal of Clinical Gastroenterology 2003;37:330-5. [DOI: 10.1097/00004836-200310000-00012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
101 Pessoa MG, Wright TL. Overview of HBV therapy. Adv Exp Med Biol 1999;458:1-10. [PMID: 10549374 DOI: 10.1007/978-1-4615-4743-3_1] [Reference Citation Analysis]
102 Renner EL, Lavanchy D. [Drug therapy of chronic hepatitis B]. Soz Praventivmed 1998;43 Suppl 1:S21-3, S95-7. [PMID: 9833259 DOI: 10.1007/BF02042168] [Reference Citation Analysis]
103 Aoki FY, Hayden FG, Dolin R. Antiviral Drugs (Other than Antiretrovirals). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 565-610. [DOI: 10.1016/b978-0-443-06839-3.00041-2] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
104 Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol. 2000;32:300-306. [PMID: 10707871 DOI: 10.1016/s0168-8278(00)80076-8] [Cited by in Crossref: 178] [Cited by in F6Publishing: 41] [Article Influence: 8.1] [Reference Citation Analysis]
105 Zoulim F, Trépo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol 1998;29:151-68. [PMID: 9696505 DOI: 10.1016/s0168-8278(98)80191-8] [Cited by in Crossref: 79] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
106 Simpson ND, Simpson PW, Ahmed AM, Nguyen MH, Garcia G, Keeffe EB, Ahmed A. Prophylaxis Against Chemotherapy-Induced Reactivation of Hepatitis B Virus Infection With Lamivudine: . Journal of Clinical Gastroenterology 2003;37:68-71. [DOI: 10.1097/00004836-200307000-00017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
107 Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs. 1999;58:101-141. [PMID: 10439933 DOI: 10.2165/00003495-199958010-00015] [Cited by in Crossref: 96] [Cited by in F6Publishing: 78] [Article Influence: 4.2] [Reference Citation Analysis]
108 Shlomai A. Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology 2003;37:764-70. [DOI: 10.1053/jhep.2003.50146] [Cited by in Crossref: 190] [Cited by in F6Publishing: 185] [Article Influence: 10.0] [Reference Citation Analysis]
109 Maddrey WC. Hepatitis B: an important public health issue. J Med Virol. 2000;61:362-366. [PMID: 10861647 DOI: 10.1002/1096-9071(200007)61:3%3C362::AID-JMV14%3E3.0.CO;2-I] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Kumar PN, Patel P. Lamivudine for the treatment of HIV. Expert Opinion on Drug Metabolism & Toxicology 2009;6:105-14. [DOI: 10.1517/17425250903490418] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
111 Delaney WE 4th, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother. 2001;12:1-35. [PMID: 11437320 DOI: 10.1177/095632020101200101] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 3.7] [Reference Citation Analysis]
112 Vassiliadis T, Garipidou V, Tziomalos K, Perifanis V, Giouleme O, Vakalopoulou S. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy—A prospective case series. Am J Hematol 2005;80:197-203. [DOI: 10.1002/ajh.20471] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
113 Anderson AL, Banks KE, Pontoglio M, Yaniv M, McLachlan A. Alpha/beta interferon differentially modulates the clearance of cytoplasmic encapsidated replication intermediates and nuclear covalently closed circular hepatitis B virus (HBV) DNA from the livers of hepatocyte nuclear factor 1alpha-null HBV transgenic mice. J Virol. 2005;79:11045-11052. [PMID: 16103155 DOI: 10.1128/jvi.79.17.11045-11052.2005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
114 Scotto G, Palumbo E, Fazio V, Cibelli DC, Saracino A, Tartaglia A, Angarano G. Prolonged lamivudine treatment in patients with chronic active anti-HBe-positive hepatitis. Am J Ther 2006;13:218-22. [PMID: 16772763 DOI: 10.1097/01.mjt.0000158341.93235.5e] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
115 Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999;17:394-8. [PMID: 10458258 DOI: 10.1200/JCO.1999.17.1.394] [Cited by in Crossref: 134] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
116 Lim LL, Wai CT, Lee YM, Kong HL, Lim R, Koay E, Lim SG. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002;16:1939-44. [PMID: 12390103 DOI: 10.1046/j.1365-2036.2002.01364.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 2.6] [Reference Citation Analysis]
117 Gutfreund KS, Williams M, George R, Bain VG, Ma MM, Yoshida EM, Villeneuve JP, Fischer KP, Tyrrel DL. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 2000;33:469-75. [PMID: 11020004 DOI: 10.1016/s0168-8278(00)80284-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
118 Ladner SK, Miller TJ, King RW. The M539V Polymerase Variant of Human Hepatitis B Virus Demonstrates Resistance to 2′-Deoxy-3′-Thiacytidine and a Reduced Ability to Synthesize Viral DNA. Antimicrob Agents Chemother 1998;42:2128-31. [DOI: 10.1128/aac.42.8.2128] [Cited by in Crossref: 36] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
119 Jung YO, Lee YS, Yang WS, Han DJ, Park JS, Park S. TREATMENT OF CHRONIC HEPATITIS B WITH LAMIVUDINE IN RENAL TRANSPLANT RECIPIENTS1: . Transplantation 1998;66:733-7. [DOI: 10.1097/00007890-199809270-00007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 2.0] [Reference Citation Analysis]
120 Scotto G, Palumbo E, Fazio V, Saracino A, Angarano G. Extended lamivudine treatment in patients affected by chronic active anti-Hbe positive hepatitis. J Chemother 2006;18:43-8. [PMID: 16572893 DOI: 10.1179/joc.2006.18.1.43] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
121 Korba BE, Cote P, Hornbuckle W, Schinazi R, Gerin JL, Tennant BC. Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks. Antiviral Res. Antiviral Res. 2000;45:19-32. [PMID: 10774587 DOI: 10.1016/s0166-3542(99)00072-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
122 Hann HL. Hepatocellular carcinoma in Asian Americans. Cancer 1998;83:1723-9. [DOI: 10.1002/(sici)1097-0142(19981015)83:8+<1723::aid-cncr13>3.0.co;2-w] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
123 Jiang J, Hu P, Xie H, Chen H, Fan F, Harker A, Johnson MA. The pharmacokinetics of lamivudine in healthy Chinese subjects. Br J Clin Pharmacol 1999;48:250-3. [PMID: 10417505 DOI: 10.1046/j.1365-2125.1999.00984.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
124 Strasser SI, Mcdonald GB. Hepatitis Viruses and Hematopoietic Cell Transplantation: A Guide to Patient and Donor Management. Blood 1999;93:1127-36. [DOI: 10.1182/blood.v93.4.1127.404k01_1127_1136] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
125 Lai CL, Yuen MF. Profound suppression of hepatitis B virus replication with lamivudine. J Med Virol 2000;61:367-73. [DOI: 10.1002/1096-9071(200007)61:3<367::aid-jmv15>3.0.co;2-a] [Cited by in Crossref: 29] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
126 Dusheiko G. Lamivudine treatment of chronic hepatitis B. Rev Med Virol 1998;8:153-9. [DOI: 10.1002/(sici)1099-1654(199807/09)8:3<153::aid-rmv228>3.0.co;2-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
127 Yao F, Gish RG. Treatment of chronic hepatitis B: New antiviral therapies. Curr Gastroenterol Rep 1999;1:20-6. [DOI: 10.1007/s11894-999-0082-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
128 Sablon E, Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci. 2005;2:8-16. [PMID: 15968334 DOI: 10.7150/ijms.2.8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
129 Seta T, Yokosuka O, Imazeki F, Tagawa M, Saisho H. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol 2000;60:8-16. [PMID: 10568756 DOI: 10.1002/(sici)1096-9071(200001)60:1<8::aid-jmv2>3.0.co;2-u] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
130 Clark F, Drummond M, Chambers S, Chapman B, Patton W. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin’s lymphoma. Annals of Oncology 1998;9:385-7. [DOI: 10.1023/a:1008206519571] [Cited by in Crossref: 82] [Cited by in F6Publishing: 6] [Article Influence: 3.4] [Reference Citation Analysis]
131 Yeo W, Steinberg JL, Tam JS, Chan PK, Leung NW, Lam KC, Mok TS, Johnson PJ. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999;59:263-9. [DOI: 10.1002/(sici)1096-9071(199911)59:3<263::aid-jmv1>3.0.co;2-x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
132 Yao J, Yu W, Chang Y, Ren J, Xu D, Han S, Lin J. Targeted screening of SiRNA directed HBV polymerase gene for effective inhibition of HBV expression. J Huazhong Univ Sci Technol [Med Sci ] 2008;28:266-71. [DOI: 10.1007/s11596-008-0308-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
133 Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000;61:362-6. [PMID: 10861647 DOI: 10.1002/1096-9071(200007)61:3<362::aid-jmv14>3.0.co;2-i] [Cited by in Crossref: 201] [Cited by in F6Publishing: 64] [Article Influence: 9.1] [Reference Citation Analysis]
134 Li MW, Hou W, Wo JE, Liu KZ. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance. J Zhejiang Univ Sci B. 2005;6:664-667. [PMID: 15973769 DOI: 10.1631/jzus.2005.b0664] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
135 Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007; 13(1): 125-140 [PMID: 17206760 DOI: 10.3748/wjg.v13.i1.125] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
136 Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol. 2010;116:147-159. [PMID: 20567182 DOI: 10.1097/aog.0b013e3181e45951] [Cited by in Crossref: 120] [Cited by in F6Publishing: 39] [Article Influence: 10.0] [Reference Citation Analysis]
137 B??hler L, Mentha G, Giostra E, Cretin N, Rubbia L, Morel P, Wernli M. AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR RECURRENT MALIGNANT LYMPHOMA AFTER LIVER TRANSPLANTATION: . Transplantation 1999;67:630-1. [DOI: 10.1097/00007890-199902270-00024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
138 Yilmaz M, Dagdas S, Güler N, Aki SZ, Aköz AG, Özet G, Ayli M, Saritas U. Lamivudine therapy in acute leukemia patients who are hepatitis B surface antigen carriers. Hematology 2003;8:393-6. [PMID: 14668034 DOI: 10.1080/10245330310001594234] [Reference Citation Analysis]
139 Arai S, Lee LA, Vogelsang GB. A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J Hematother Stem Cell Res. 2002;11:215-229. [PMID: 11983095 DOI: 10.1089/152581602753658420] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
140 Hagmeyer KO, Pan Y. Role of Lamivudine in the Treatment of Chronic Hepatitis B Virus Infection. Ann Pharmacother 1999;33:1104-12. [DOI: 10.1345/aph.18452] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
141 Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999;29:889-896. [PMID: 10051494 DOI: 10.1002/hep.510290321] [Cited by in Crossref: 346] [Cited by in F6Publishing: 312] [Article Influence: 15.0] [Reference Citation Analysis]
142 Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int. 2005;25:1097-1107. [PMID: 16343058 DOI: 10.1111/j.1478-3231.2005.01177.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 4.4] [Reference Citation Analysis]
143 Lau G, Carman W, Locarnini S, Okuda K, Lu Z, Williams R, Lam S. Treatment of chronic hepatitis B virus infection: An Asia–Pacific perspective. Journal of Gastroenterology and Hepatology 2002;14:3-12. [DOI: 10.1046/j.1440-1746.1999.01812.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
144 Selimoglu MA, Aydogdu S, Unal F, Zeytinoglu A, Yüce G, Yagci RV. Alpha interferon and lamivudine combination therapy for chronic hepatitis B in children. Pediatr Int. 2002;44:404-408. [PMID: 12139566 DOI: 10.1046/j.1442-200x.2002.01589.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
145 Ji HY, Lee HW, Yoon Y, Lee HS. Quantification of lamivudine in human plasma by hydrophilic interaction chromatography-tandem mass spectrometry: Liquid Chromatography. J Sep Science 2010;33:948-54. [DOI: 10.1002/jssc.200900674] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
146 Staschke KA, Colacino JM. Drug discovery and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Prog Drug Res. 2001;Spec No:111-183. [PMID: 11548207 DOI: 10.1007/978-3-0348-7784-8_4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
147 Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology. 1998;27:628-633. [PMID: 9462667 DOI: 10.1002/hep.510270243] [Cited by in Crossref: 277] [Cited by in F6Publishing: 261] [Article Influence: 11.5] [Reference Citation Analysis]
148 de Fraga RS, Van Vaisberg V, Mendes LCA, Carrilho FJ, Ono SK. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol 2020;55:496-514. [PMID: 32185517 DOI: 10.1007/s00535-020-01680-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
149 Nery J, Weppler D, Lavandera R, Nery Avila C, Magill A, Rodriguez M, Reddy K, Schiff E, Tzakis A. Developing strategies for prevention and treatment of recurrent HBV in liver transplantation. Transplantation Proceedings 1999;31:485-6. [DOI: 10.1016/s0041-1345(98)01720-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
150 Kobayashi M, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Sezaki H, Kobayashi M, Kawamura Y, Suzuki Y, Arase Y. Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. Hepatol Res. 2010;40:125-134. [PMID: 19788696 DOI: 10.1111/j.1872-034x.2009.00565.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
151 Lam W, Li Y, Liou JY, Dutschman GE, Cheng YC. Reverse transcriptase activity of hepatitis B virus (HBV) DNA polymerase within core capsid: interaction with deoxynucleoside triphosphates and anti-HBV L-deoxynucleoside analog triphosphates. Mol Pharmacol 2004;65:400-6. [PMID: 14742682 DOI: 10.1124/mol.65.2.400] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
152 Korba BE, Cote P, Hornbuckle W, Tennant BC, Gerin JL. Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology. 2000;31:1165-1175. [PMID: 10796894 DOI: 10.1053/he.2000.5982] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 3.1] [Reference Citation Analysis]
153 Littler E, Oberg B. Achievements and challenges in antiviral drug discovery. Antivir Chem Chemother. 2005;16:155-168. [PMID: 16004079 DOI: 10.1177/095632020501600302] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
154 Lai CL. Antiviral therapy for hepatitis B and C in Asians. J Gastroenterol Hepatol 1999;14 Suppl:S19-21. [PMID: 10382633 DOI: 10.1046/j.1440-1746.1999.01879.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
155 Wong DK, Yuen MF, Yuan H, Sum SS, Hui CK, Hall J, Lai CL. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology. 2004;40:727-737. [PMID: 15349913 DOI: 10.1002/hep.20353] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 4.9] [Reference Citation Analysis]
156 Kitay-cohen Y, Ben-ari Z, Tur-kaspa R, Fainguelernt H, Lishner M. EXTENSION OF TRANSPLANTATION FREE TIME BY LAMIVUDINE IN PATIENTS WITH HEPATITIS B-INDUCED DECOMPENSATED CIRRHOSIS: . Transplantation 2000;69:2382-3. [DOI: 10.1097/00007890-200006150-00028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
157 Chen C, Lee C, Lu S, Changchien C, Wang J, Wang J, Hung C, Hu T. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. Journal of Hepatology 2006;44:76-82. [DOI: 10.1016/j.jhep.2005.08.022] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
158 Kim JK, Lee HJ, Lee YJ, Chun JY, Lee IK, Lim YS, Suh DJ, Ko SY, Kim MH, Oh HB. Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. J Virol Methods. 2008;149:76-84. [PMID: 18291537 DOI: 10.1016/j.jviromet.2008.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
159 Zoulim F. Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies. Antiviral Res. 1999;44:1-30. [PMID: 10588330 DOI: 10.1016/s0166-3542(99)00056-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
160 Pramoolsinsup C. Management of viral hepatitis B. J Gastroenterol Hepatol. 2002;17 Suppl:S125-S145. [PMID: 12000599 DOI: 10.1046/j.1440-1746.17.s1.3.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 2.4] [Reference Citation Analysis]
161 Pardo M, Bartolomé J, Carreño V. Current therapy of chronic hepatitis B. Arch Med Res 2007;38:661-77. [PMID: 17613358 DOI: 10.1016/j.arcmed.2006.12.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
162 Kobayashi M, Suzuki F, Akuta N, Suzuki Y, Arase Y, Ikeda K, Hosaka T, Sezaki H, Kobayashi M, Iwasaki S. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. J Med Virol. 2006;78:1276-1283. [PMID: 16927289 DOI: 10.1002/jmv.20701] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]